Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM
April 17th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how the preliminary results from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory multiple myeloma (R/R MM) highlight promising efficacy in triple-class and penta-class refractory patients, potentially reshaping treatment strategies and challenging existing paradigms in managing heavily pretreated myeloma.
Application of Real-World Evidence in Selecting CAR T in R/R MM
April 17th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with relapsed/refractory multiple myeloma (R/R MM), highlighting the critical importance of translating clinical trial data into practical treatment strategies.
Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT
April 14th 2025, 6:20pm
Oncology Nursing Society Congress
Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.
Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer
April 14th 2025, 5:00pm
Oncology Nursing Society Congress
Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.
CEPHEUS Data Support D-VRd in Transplant-Ineligible or -Deferred Patients With Myeloma Who Can Tolerate Bortezomib
April 13th 2025, 12:00pm
Oncology Nursing Society Congress
D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.
Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma
April 12th 2025, 6:00pm
Oncology Nursing Society Congress
Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.
Retrospective Study Shows Variability of Interventions for Blinatumomab-Related Neurotoxicity in Hematologic Malignancies
April 11th 2025, 8:28pm
Oncology Nursing Society Congress
A retrospective study found that interventions for patients experiencing grade 2 vs 3 blinatumomab-associated ICANS were not consistently implemented.
PROs, Gene Expression Vary Among Patients With AML Undergoing Induction Chemo
April 11th 2025, 8:07pm
PROs and gene expression in peripheral blood varied in patients with acute myeloid leukemia receiving induction chemotherapy.
Aguilar-Clancy on the Importance of Individualized Nutritional Support as a Component of Oncology Care
April 11th 2025, 7:46pm
Oncology Nursing Society Congress
Claudia Aguilar Clancy, FNP-C, AOCNP, discusses the importance of individualized nutritional support as a component of oncology care.
Dr Kozek on Oncology Nurses’ Perceived Difficulties in Providing Palliative Care to Adult Patients
April 11th 2025, 7:42pm
Oncology Nursing Society Congress
Caroline Kozek, DNP, RN, AGNP-C, OCN, discusses a study assessing oncology nurses’ perceived difficulties in providing palliative care to adult patients.
Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma
April 11th 2025, 7:41pm
Oncology Nursing Society Congress
Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.
Educational Intervention Seeks to Decrease Barriers to Cancer Clinical Trial Enrollment
April 11th 2025, 7:03pm
Oncology Nursing Society Congress
Cancer clinical trial education is valuable and may promote current and future participation.
Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma
April 11th 2025, 6:30pm
Oncology Nursing Society Congress
Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.
Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration
April 10th 2025, 11:40pm
Oncology Nursing Society Congress
Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.
Dr Mahon on the Importance of Integrating Genomic Science Into Oncology Practice
April 10th 2025, 8:47pm
Oncology Nursing Society Congress
Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.
Timely G-CSF Administration Is Key for Hematologic AE Management in mPDAC Receiving NALIRIFOX
April 10th 2025, 8:30pm
Oncology Nursing Society Congress
The association between greater hematologic AEs and increased OS necessitates early receipt of G-CSF after NALIRIFOX infusion for patients with PDAC.
Social Determinants of Health Significantly Affect Some Psychoneurological Symptoms in Breast Cancer Survivors
April 10th 2025, 8:22pm
Oncology Nursing Society Congress
Social factors including financial needs and stress caused increased levels of psychoneurological symptoms in breast cancer survivors.
A Mount Sinai Steering Committee Helps Merge Clinical Trials Into the SOC in Oncology
April 10th 2025, 7:54pm
Oncology Nursing Society Congress
A clinical trial steering committee from the Mount Sinai Health System helped integrate therapeutic clinical trials into the SOC for patients with cancer.
Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC
April 10th 2025, 6:55pm
Oncology Nursing Society Congress
Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.
Dr Lee on the Role of Integrative Medicine in Oncology Care
April 10th 2025, 6:49pm
Oncology Nursing Society Congress
Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.